Made in Russia. How Can Domestic Pharmaceutical Products Win Over Consumer Trust?

5 June, 14:30–16:00 Congress Centre, zone B, 2nd floor, conference hall B2
Broadcast
The success of Russia’s goal to ensure its sustainable national drug sovereignty not only depends on the effectiveness of regulatory decisions, but also on the level of public confidence in domestic drugs. The strategies for improving the reputation of the Russian pharmaceutical industry should be based on constructive interaction between government, business, and the professional and scientific community in the public’s interests. Russia needs sound communication strategies based on the principles of information openness among all institutions involved in this process, a well-reasoned and consistent dialogue, a solid body of evidence, and the high quality and safety profile of domestic medicines. In terms of the information and awareness agenda, we need to create open platforms for cooperation that representatives of the medical community will be able to use to visit pharmaceutical enterprises and learn first-hand about the results of advanced technologies and developments, drug effectiveness indicators, and the quality assurance system in manufacturing in order to become ambassadors of Russian pharmaceutical products for the patient community. What trust factors influence the image of Russian pharmaceutical products and how should we manage them? Which institutions should represent the interests of the Russian pharmaceutical industry in the face of public opinion and what is the best way to involve them in this process? What effective tools can destroy stereotypes in society’s attitude towards domestic drugs and help increase public confidence in Russian medicines?

Broadcast

Image